Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia

Haematologica

Volumn 96, Issue 9, 2011, Pages 1269-1275

  Afable, Manuel G ^a   Shaik, Mohammed ^a   Sugimoto, Yuka ^a   Elson, Paul ^b   Clemente, Michael ^a   Makishima, Hideki ^a   Sekeres, Mikkael A ^a   Lichtin, Alan ^a   Advani, Anjali ^a   Kalaycio, Matt ^a   Tiu, Ramon V ^a   O'Keefe, Christine L ^a   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti thymocyte globulin; Aplastic anemia; Cytokine gene polymorphism

Indexed keywords

CYCLOSPORIN; GENZYME; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; APLASTIC ANEMIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; HORSE; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREDICTION; RABBIT; RETICULOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOKINES; FEMALE; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RABBITS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052372971     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042622     Document Type: Article

References (36)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-19.
2. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991; 324(19):1297-304.
3. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003; 101(4):1236-42.
4. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5.
5. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-8.
6. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007; 109(8):3219-24.
7. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest. 2004;114(9): 1209-17.
8. Chen G, Kook H, Zeng W, Young NS, Maciejewski JP. Is there a direct effect of antithymocyte globulin on hematopoiesis? J Hematology. 2004; 5:655-61.
9. Flynn J, Cox CV, Rizzo S, Foukaneli T, Rice K, Murphy M, et al. Direct binding of antithymoctye globulin to haemopoietic progenitor cells in aplastic anaemia. Br J Haematol. 2003; 122(2):289-97.
10. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol. 2000; 111(4):1164-9.
11. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008; 111(7):3675-83.
12. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999; 107(2):330-4.
13. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006; 133(6):622-7.
14. Kadia T, Ravandi F, Garcia-Manero G, Jabbour E, Borthakur G, Estrov Z, et al. Updated results of combination cytokine immunotherapy in the treatment of aplastic anemia and myelodysplastic syndrome (MDS). Blood. 2010;116(22):4422-9.
15. Vallejo C, Montesinos P, Rosell A, Brunet S, Perez E, Petit J, et al. Comparison between lymphoglobuline-and thymoglobulinebased immunosuppressive therapy as a first-line treatment for patients with aplastic anemia. Haematologica. 2009; 94(S. 2):451.
16. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006; 34(7):826-31.
17. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010; 89(9):851-9.
18. Maschan MA, Novichkova G, Baidildina D, Suntzova E, Kravchenko E, Goronkova O, et al. Horse ATG (ATGAM) versus rabbit ATG (Fresenius) for treatment of aplastic anemia in children: results of prospective double-blind randomised single centre trial. Bone Marrow Transplant. 2004;33: S3-S79.
19. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009; 144(2):206-16.
20. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositolanchored protein-deficient clones. Br J Haematol. 2001; 115(4):1015-22.
21. Mohan S, Clemente MJ, Afable M, Wlodarski MW, Cazzolli HN, Lichtin AE, Maciejewski JP. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in large granular lymphocyte leukemia. Haematologica. 2009; 94(10): 1407-14.
22. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood. 2006;108(8):2632-41.
23. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009;23(7):1297-302.
24. Scheinberg P, Wu C, Scheinberg P, Weinstein B, Nunez O, Sload E, Young N. A randomized trial of horse globulin in severe acquired aplastic anemia. Blood (ASH Annual Meeting Abstracts) 2010; Abstract LBA-4.
25. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003;17(11):2101-6.
26. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997; 99(3):699-705.
27. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120(4):679-84.
28. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004; 18(3):460-5.
29. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunsuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308-14.
30. Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84(2):154-9.
31. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001; 98(13):3513-9.
32. Saunthararajah Y, Nakamura R, Nam J-M, Robyn J, Loberiza F, Maciejewski JP, et al. HLA DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia, and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2000;100(5):1570-4.
33. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997; 336(19):1365-72.
34. Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/ enhancer polymorphism in patients with aplastic anemia. Ann Hematol. 2002; 81(10):566-9.
35. Fermo E, Bianchi P, Barcellini W, Pedotti P, Boschetti C, Alfinito F, et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogenet. 2004; 31(6):267-9.
36. Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995; 86(4):1487-92.